Capital Access Group - TheraCryf | £1.1m raise progressing Ox-1 to clinical trial
Research on TheraCryf PLC (TCF:LON) from Capital Access Group
TheraCryf has announced an equity raise of £1.05m, gross by way of a placing and subscription focusing on completing the clinic-enabling programme for the company's Ox-1 lead clinical asset with the aim of securing a partnering/out-licensing deal to support the future costs of the programme. This is coupled with the potential to undertake the next stage Phase 1 clinical trial in Australia which offers an accelerated and potentially more cost-effective route to generating Phase 1 clinical trial data that would be generally acceptable to potential partners and to regulators in the US and Europe. The raise is priced at a tight 5% discount to the close against the backdrop of significant partnering and strong industry interest in Ox-1 specifically and neuropsychiatric drugs more generally. Progression to clinical trial readiness of Ox-1 is running ahead of plan, bolstered by a process patent filing that could extend commercial protection through 2046.
View Full ResearchDisclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
